Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Therapy

Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia

Leukemia volume 21, pages 2240–2245 (2007)Cite this article

Abstract

CMC-544 (inotuzumab ozogamicin) is a CD22-specific cytotoxic immunoconjugate of calicheamicin intended for the treatment of B-lymphoid malignancies. This preclinical study investigated antitumor activity of CMC-544 against CD22+ acute lymphoblastic leukemia (ALL). CMC-544 inhibited in vitro growth of ALL cell lines more potently than that of Ramos B-lymphoma cells. When administered to nude mice with established sc xenografts of REH ALL, CMC-544 caused dose-dependent inhibition of xenograft growth producing complete tumor regression and cures in tumor-bearing mice at the highest dose of 160 μg/kg of conjugated calicheamicin. In contrast, a nonbinding control conjugate was 16-fold less effective than CMC-544 in inhibiting growth of REH ALL xenografts. When REH cells were injected intravenously in scid mice and allowed to disseminate systemically, mice developed hind-limb paralysis that was effectively prevented by treatment with CMC-544. Flow cytometric analysis of cells recovered from the bone marrow from mice with disseminated disease verified the presence of engrafted ALL cells. Significantly reduced numbers of ALL cells were recovered from the bone marrow of CMC-544-treated mice than from vehicle-treated mice with disseminated disease. The anti-leukemia activity of CMC-544 demonstrated here further supports clinical evaluation of CMC-544 for the treatment of CD22+ leukemia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Pui C-H, Evans E . Treatment of acute lymphoblastic leukemia. New Engl J Med 2006; 354: 166–178.

    Article  CAS  Google Scholar 

  2. American Cancer Society. Cancer Facts and Figures 2006. American Cancer Society Inc.: Atlanta, GA, 2006, pp 1–56.

  3. Stewart BW, Kleihus P (eds) World Cancer Report. IARC Press: Lyon, 2003, Pages 1–352.

    Google Scholar 

  4. Parkins DM, Whelan SL, Farley J, Teppo L, Thomas DB . Cancer incidence in 5 continents. IARC: Lyon, Vol. VIII. IARC Scient. Publ. No. 155 2002, pp 1–1286.

  5. Marugame T, Kamo K-I, Katanoda K, Ajiki W, Sobue T . Cancer incidence and incidence rates in Japan 2000. Jpn J Clin Oncol 2006; 36: 668–675.

    Article  Google Scholar 

  6. Hamann P, Hinman L, Hollander I, Beyer C, Lindh D, Holcomb R et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconj Chem 2002; 13: 47–58.

    Article  CAS  Google Scholar 

  7. Berger M, Leopold L, Dowell J, Korth-Bradley J, Sherman M . Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Invest New Drugs 2002; 20: 395–406.

    Article  CAS  Google Scholar 

  8. Burnett AK, Kell WJ, Goldstone AH, Milligan D, Hunter A, Prentice AG et al. The addition of gentuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity. Preliminary analysis of 1115 patients in the MRC AML15 trial. Blood 2006; 108: 13a.

    Google Scholar 

  9. Advani A, Gisselbrecht EGC, Rohatiner A, Rosen S, Smith MR, Boni J et al. Preliminary report of a phase 1 study of CMC-544, an antibody-targeted chemotherapy agent, in patients with B-cell non-Hodgkin's lymphoma (NHL). Blood 2005; 106: 230a.

    Google Scholar 

  10. Fayad L, Patel H, Verhoef G, Czuczman M, Foran J, Gine E et al. Clinical activity of the immunoconjugate CMC-544 in B-cell malignancies: Preliminary report of the expanded maximum tolerated dose (MTD) cohort of a phase 1 study. Blood 2006; 108: 766a.

    Google Scholar 

  11. DiJoseph JF, Armellino DC, Boghaert E, Khandke K, Dougher MM, Sridharan L et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B lymphoid malignancies. Blood 2004; 103: 1807–1814.

    Article  CAS  Google Scholar 

  12. DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR et al. Potent and specific anti-tumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004; 10: 8620–8629.

    Article  CAS  Google Scholar 

  13. Bene M . Immunophenotyping of acute leukemias. Immunol Lett 2005; 98: 9–21.

    Article  CAS  Google Scholar 

  14. Rezaei A, Adib M, Mokarian F, Tebianian M, Nassiri R . Leukemia markers expression of peripheral blood vs. bone marrow blasts using flow cytometry. Med Sci Monit 2003; 9: 359–362.

    Google Scholar 

  15. Gudowius S, Recker K, Laws H-J, Dirksen U, Troger A, Wieczorek U et al. Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin Pediatr 2006; 218: 327–333.

    Article  CAS  Google Scholar 

  16. Gökbuget N, Hoelzer D . Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 2004; 4: 201–205.

    Article  Google Scholar 

  17. Herrera L, Farah RA, Pellegrini VA, Aquino DB, Sandler ES, Buchanan GR et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 2000; 14: 853–858.

    Article  CAS  Google Scholar 

  18. Borowitz MJ, Carroll WL, Adamson PC, Cairo MS, Goldenberg DM, Wegener WA et al. Effective targeting of leukemic cells in children with B-precursor acute lymphoblastic leukemia treated with anti-CD22 (epratuzumab). A children's Oncology Group Study. Blood 2006; 108: 13a.

    Google Scholar 

  19. Rubin CM, Carrino JJ, Dickler MN, Leibowitz D, and Smith SD, Westbrook CA . Heterogeneity of genetic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia. Proc Natl Acad Sci 1988; 85: 2795–2799.

    Article  CAS  Google Scholar 

  20. Fukushima S, Yamada T, Hashiguchi A, Nakata Y, Hata J . Augmentation of human leukemic cell invasion by activation of a small GTP-binding protein Rho. Exp Hematol 2000; 28: 391–400.

    Article  CAS  Google Scholar 

  21. Zein N, Sinha A, McGahren W, Ellestad G . Calicheamicin γI: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988; 240: 1198–1201.

    Article  CAS  Google Scholar 

  22. Zwaan CM, Reinhardt D, Jurgens H, Huismans DR, Hahlen K, Smith OP et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia 2003; 17: 468–470.

    Article  CAS  Google Scholar 

  23. Boghaert ER, Khandke K, Sridharan L, Armellino D, Dougher M, DiJoseph JF et al. Tumoricidal effect of calicheamicin immuno-conjugates using a passive targeting strategy. Int J Oncol 2006; 28: 675–684.

    CAS  PubMed  Google Scholar 

  24. Tedder TF, Tuscano J, Sato S, Kehrl JH . CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Ann Rev Immunol 1997; 15: 481–504.

    Article  CAS  Google Scholar 

  25. Crocker PR, Varki A . Siglecs, sialic acids and innate immunity. Trends Immunol 2001; 22: 337–342.

    Article  CAS  Google Scholar 

  26. Boue DR, LeBien TW . Expression and structure of CD22 in acute leukemia. Blood 1988; 71: 1480–1486.

    CAS  PubMed  Google Scholar 

  27. Lucio P, Gaipa G, van Lochem EG, van Wering ER, Porwit-MacDonald A, Faria T et al. BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. Leukemia 2001; 15: 1185–1192.

    Article  CAS  Google Scholar 

  28. Golay J, DiGaetano N, Amico D, Cittera E, Barbui AM, Giavazzi R et al. Gemtuzumab ozogamicin (Mylotarg) had therapeutic activity against CD33+ acute lymphoblastic leukemia in vitro and in vivo. Br J Haematol 2005; 128: 310–317.

    Article  CAS  Google Scholar 

  29. Balduzzi A, Rossi V, Corral L, Bonanomi S, Longoni D, Rovelli A et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia 2003; 17: 2247–2248.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr Philip Hamann for helpful discussions in preparation of this manuscript. All authors are employed by Wyeth Research. CMC-544 is a collaboration product being jointly developed by Wyeth Research and UCB Celltech, Slough, UK.

Author information

Authors and Affiliations

  1. Oncology Discovery Research, Wyeth Research, Pearl River, NY, USA

    J F DiJoseph, M M Dougher, D C Armellino, D Y Evans & N K Damle

Authors
  1. J F DiJoseph
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M M Dougher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D C Armellino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Y Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N K Damle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N K Damle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DiJoseph, J., Dougher, M., Armellino, D. et al. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21, 2240–2245 (2007). https://doi.org/10.1038/sj.leu.2404866

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404866

Keywords

This article is cited by

Search

Advanced search

Quick links